Ocrelizumab in pediatric multiple sclerosis.

[1]  S. Cohan,et al.  Clinical outcomes of patients with multiple sclerosis treated with ocrelizumab in a US community MS center: an observational study , 2021, BMJ Neurology Open.

[2]  H. Weiner,et al.  Improved relapse recovery in paediatric compared to adult multiple sclerosis. , 2020, Brain : a journal of neurology.

[3]  A. Bar-Or,et al.  Rituximab in patients with pediatric multiple sclerosis and other demyelinating disorders of the CNS: Practical considerations , 2020, Multiple sclerosis.

[4]  E. Waubant,et al.  Real‐World Effectiveness of Initial Disease‐Modifying Therapies in Pediatric Multiple Sclerosis , 2020, Annals of neurology.

[5]  M. Moodley,et al.  Newer Treatment Approaches in Pediatric-Onset Multiple Sclerosis , 2019, Current Treatment Options in Neurology.

[6]  R. Greil,et al.  Aging restricts the ability of mesenchymal stem cells to promote the generation of oligodendrocytes during remyelination , 2019, Glia.

[7]  J. Lechner-Scott,et al.  Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis , 2019, JAMA.

[8]  David H. Miller,et al.  Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria , 2017, The Lancet Neurology.

[9]  A. Traboulsee,et al.  Ocrelizumab versus Interferon Beta‐1a in Relapsing Multiple Sclerosis , 2017, The New England journal of medicine.

[10]  B. Weinshenker,et al.  Poor early relapse recovery affects onset of progressive disease course in multiple sclerosis , 2015, Neurology.

[11]  H. Weiner,et al.  Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. , 2015, JAMA neurology.

[12]  Carsten Lukas,et al.  Towards the implementation of ‘no evidence of disease activity’ in multiple sclerosis treatment: the multiple sclerosis decision model , 2015, Therapeutic advances in neurological disorders.

[13]  Y. Ben-Shlomo,et al.  Long-term outcome of paediatric-onset multiple sclerosis: a population-based study , 2012, Journal of Neurology, Neurosurgery & Psychiatry.

[14]  T. Chitnis,et al.  Pathogenesis of Pediatric Multiple Sclerosis , 2012, Journal of child neurology.

[15]  A. Ghezzi,et al.  Consensus statement: evaluation of new and existing therapeutics for pediatric multiple sclerosis , 2012, Multiple sclerosis.

[16]  M Ramanathan,et al.  Magnetic resonance imaging characteristics of children and adults with paediatric-onset multiple sclerosis. , 2009, Brain : a journal of neurology.

[17]  D. Paty,et al.  Early onset multiple sclerosis: A longitudinal study , 2002, Neurology.

[18]  P. Huppke,et al.  Therapy of highly active pediatric multiple sclerosis , 2019, Multiple sclerosis.

[19]  P. Vermersch,et al.  Natural history of multiple sclerosis with childhood onset. , 2007, The New England journal of medicine.

[20]  Frcp,et al.  Pediatric multiple sclerosis Escalation and emerging treatments , 2022 .

[21]  A. Ghezzi,et al.  Pediatric multiple sclerosis Clinical features and outcome , 2022 .